The recent discovery of a new isoform of estrogen receptor (ER) ␤ has prompted the reexamination of estrogen action on target organs. Here, we describe the endometrial expression of human ER␤ and compare its distribution with that of ER␣ in the endometrial functional zone. Using immunocytochemistry with well characterized polyclonal antibodies against ER␤, we have detected specific ER␤ expression in all endometrial compartments (glandular, stromal, and vascular); the specificity of the immunostaining is confirmed by lack of staining of the uterine sections with anti-ER␤ antibodies previously incubated with peptide preparation. The highest levels of ER␤ expression are observed in epithelial cells during the periovulatory period (days 14 and 15), as well as in stromal cells and cells of the vascular wall in the late-secretory phase; both smooth muscle cells and endothelial cells express ER␤, as deduced from immunocytochemistry and RT-PCR analysis. ER␤ staining is usually low compared with that of ER␣, except at days 24 -26. The presence of ER␤ in decidualized stromal cells is deduced from immunocytochemistry using antismooth ␣-actin and anti-ER␤ antibodies or from RT-PCR analysis of ER␤ and insulin-like growth factor-BP transcripts in the same cells; the presence of ER␤-positive stromal cells located close to vascular smooth muscle cells during this period suggests some specific role of this receptor during decidualization. ER␣ is also present in the cells of the endometrial vascular wall, in addition to the nuclei of glandular epithelial and stromal cells. Vascular ER␣ expression is highest during the periovulatory period, suggesting a regulation by estradiol, and a role in vascular function. Moreover, different variations of ER␤ and ER␣ in arterioles might have implications for the modulation of vascular function, possibly of vascular tone, during the menstrual cycle. Finally, these data suggest that ER␤ may have important roles in endometrial function, in addition to the well known role of ER␣ in endometrial proliferation and differentiation. (J Clin Endocrinol Metab 86, 1379 -1386, 2001) E STROGENS PLAY IMPORTANT roles in the regulation of cyclic changes in the human endometrium; these estrogenic effects were thought to operate via the estrogen receptor (ER) localized in epithelial, stromal, and vascular cells. Several studies have demonstrated that the levels of this receptor in epithelial cells vary during the different stages of the menstrual cycle (1, 2). Since the cloning of ER (3), it was generally accepted that only one receptor existed. However, the discovery of a new member of the nuclear receptor superfamily with specificity for estrogens (4 -6) has prompted the reexamination of the estrogen signaling system. The novel receptor ER␤ is highly homologous to the classical ER (ER␣) and has been shown to stimulate transcription of an ER target gene (7). The most significant disparity between the two receptors lies in their tissue distribution; ER␣ messenger RNAs (mRNAs) are predominant in the uterus, mammary gland, testis, pituitary, liver, kidney, heart, and skeletal muscle, whereas ER␤ mRNAs are significantly expressed in the ovary and prostate (8, 9). These studies lead to the conclusion that there is a low to absent expression of ER␤ in the uterus, at least in the mouse (8), in agreement with some studies reporting insensitivity to estradiol (E 2 ), with respect to its effects on water imbibition, RNA and DNA synthesis, and mitosis of the glandular and stromal compartment in ER␣ knockout mice (␣ERKO) (10 -11). However, the reported preservation of other selective estrogen actions in the ␣ERKO uterus, such as induction of secretory products by the cateholestrogen 4-hydroxyestradiol (12), reinforces the need for studies about the exact endometrial distribution of the two distinct ERs.
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Few studies have reported the presence of ER␤ transcripts in the human endometrium (13, 14) , whereas immunocytochemical detection in the uterine compartments has proven difficult in the past owing to the lack of available antibodies against ER␤. In the present study, we investigated the expression of ER␤ in the human cyclic endometrium, using immunocytochemistry with previously characterized polyclonal anti-ER␤ antibodies (15, 16) , and determined the relative expression of ER␣ and ER␤ in each cell compartment.
Materials and Methods

Human uterine tissues
Endometrial biopsies were obtained from 35 cycling women (age, 22-45 yr) undergoing routine gynecological investigations in Bari University Hospital in Italy. The selected patients had no evident endocrinological problems and had normal endometrial histology; none of the patients had taken hormonal medication for at least 6 months before surgery. Informed consent was obtained from each patient, and the study was approved by the local ethical commitee. Specimens of endometrium were obtained in the proliferative (n ϭ 13), secretory (n ϭ 18), and menstrual (n ϭ 4) phases of the cycle. Endometrial dating criteria and independent histological examination were used to assess the phase of menstrual cycle (17) . All tissues were fixed in 4% buffered paraformaldehyde and embedded in paraffin.
Immunocytochemistry
Paraffin sections of 5-m thickness were routinely processed and mounted on Superfrostϩ glass slides. Immunocytochemistry of E 2 receptor(s) was performed as described previously (17, 18) , with the following modifications. Previous to immunocytochemical staining, antigen retrieval was performed on the paraffin sections by microwaving for 15 min in 0.1 M glycine-EDTA buffer (pH 3.15). The immunocytochemical staining included overnight incubation at 4 C with a mouse monoclonal antibody raised against the 67-kDa polypeptide chain of ER␣ (clone 1D5; Immunotech, Marseille, France) or affinity-purified sheep anti-ER␤ receptor antibodies (a generous gift from P. Saunders; Ref. 15) , followed by incubation with biotinylated antimouse or antisheep IgG and streptavidin-peroxidase (LSABϩ immunostaining kit; Dakopatts, Glostrup, Denmark). Peroxidase reaction was performed using aminoethylcarbazole substrate (Sigma, St. Louis, MO), as described previously (18) . Some sections were lightly counterstained with Meyer's hematoxylin. Each immunoreaction was performed twice in triplicate. A commercially available goat anti-ER␤ antibody (Santa Cruz Biotechnologies, Santa Cruz, CA) was also used in some experiments with comparable results in ER␤ distribution.
The following controls were performed: preincubation of anti-ER␤ antibody with increasing amounts of purified recombinant peptide (a gift from P. Saunders; 1-100 g/L diluted antibody) for 12 h at 4 C before immunostaining; omission of the first antibody, and finally incubation of tissue sections with nonimmune mouse (DAKO Corp.) or sheep IgG (Serotec, Oxford, UK). Tissue sections of ER␤-positive prostatic adenoma and of an ER␣-positive mammary adenocarcinoma were used as positive controls.
Adjacent sections were incubated with a marker of vascular endothelial cells, the polyclonal anti-Von Willebrand factor antibody (DAKO A/S, Glostrup, Denmark), or with a monoclonal antismooth ␣-actin antibody (Sigma) to identify smooth muscle cells of the vascular wall and decidualized stromal cells, as described previously (19, 20) .
Evaluation of immunostaining and nuclear counting
Both staining intensity and number of stained cells in the endometrial functional zone were evaluated. The relative intensity of the immunoreaction product on the whole section was graded blindly by three independent observers (G.L., G.M., and M.P.-A.) using a light microscope Axiophot (Zeiss, Oberkochen, Germany) at a ϫ100 and ϫ200 magnification; it was estimated semiquantitatively on a scale of 0 -3ϩ as: Ϫ, no detectable stain; Ϫ/ϩ, faint; ϩ, moderate; ϩϩ, strong; and ϩϩϩ, very intense staining, as described previously (18, 20, 21) . To quantify the number of immunopositive cells, immunostained nuclei were counted separately in glandular, stromal, and vascular cells of the functional zone, using a microscope (Leitz, Orthoplan) equipped with a color CDD video camera. Five different fields in each section (ϫ16 objective, 0.322 mm 2 per field) were digitized by image analysis and computerized using the Histolab program (Microvision, Evry, France), as described previously (18) . Nuclear counts were assessed blindly for each section. Values were expressed as means/per unit area Ϯ sem. Measurements were tested by ANOVA with Fisher's test. Comparisons were made using the mean values for each biopsy; Student's t test was used to compare the ER levels of each group of cells in the proliferative phase with the levels seen in luteal phase. For all statistical analysis, P less than 0.05 was considered significant.
Isolation of human endometrial cells
Isolation of stromal cells from endometrial tissue was performed using dissociation with 0.1% collagenase and 0.02% DNAse I, as described previously (22, 23) . Purity of the stromal cell preparation obtained at passage 3-4 was verified as described previously (22) 
Extraction of RNA from cells and reverse transcription (RT)-PCR analysis
Total RNA was isolated from cultures of stromal cells using a modified guanidium isothiocyanate method (Trizol; Life Technologies) (22) . A semiquantitative RT-PCR method was established [as described previously (26) and modified (25) ] to determine the amount of RNA and the number of cycles to be used in order that the quantity of PCR products is proportional to the quantity of total RNA and increases linearly as a function of the number of cycles. Amplification of ER␤ complementary DNA (cDNA) was carried out in a DNA thermal cycler at 94, 59, and 72 C for 30 sec, 1 min, and 1 min, respectively, for 39 cycles using 50 pmol of each ER␤ primer. Oligonucleotide primers were chosen from homologous parts of the coding region of the human ER␤ gene. The sense primer for human ER␤ was 5Ј-TAGTGGTCCATCGCCAGTTAT-3Ј, and the antisense primer was 5Ј-GGGAGCACACTTCACCAT-3Ј. Amplification of the constitutive glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was performed as an internal control for cDNA quantity and integrity, using 10 pmol of each primer of GAPDH, as described previously (25), for 28 cycles at 94, 55, and 72 C for 30 sec, 1 min, and 1 min, respectively. The PCR fragments were analyzed by 8% polyacrylamide gel electrophoresis, visualized by ethidium bromide staining, and the radioactivity was counted by Instant imager.
Results
ER␤ is expressed in nuclei, similarly to nuclear ER␣ labeling. ER␤ expression in the endometrial functional zone is usually weaker than in the positive control prostatic adenoma, and endometrial immunolabeling of ER␤ is less intense than that of ER␣. No immunostaining is seen in proliferative or secretory endometrium when the primary antibody is replaced by sheep IgG. Preincubation of the anti-ER␤ antibody with the immunogen recombinant peptide (100 g/mL) considerably reduces the intensity of staining (Fig. 1, A and B) .
Cellular distribution of ER␤ in the human endometrium
ER␤ immunostaining patterns were consistent in all specimens examined. Glandular, stromal, and vascular cells all express ER␤ (Figs. 1-4) . ER␤ expression in a particular cellular compartment varies according to the phase of the cycle (Table 1) , as deduced from analysis of both staining intensity and number of immunostained nuclei with computerized image analysis (see Materials and Methods and Ref. 18) . ER␤ immunostaining intensity is low in every compartment during the menstrual phase ( Table 1) .
The number of labeled epithelial nuclei is higher in the proliferative phase than in the secretory phase (ϫ1.6; P Ͻ 0.003), especially in the late-proliferative phase, whether the number of stained nuclei is expressed per total tissue unit area (Table 1) or per glandular unit area (data not shown); the glandular labeling intensity increases in the late-proliferative and early-secretory phases with a peak at days 14 and 15 ( Fig. 1, A and D) and decreases again during the secretory phase. Stromal ER␤ immunostaining is low during the menstrual cycle, except for the latesecretory phase (Fig. 1F and Table 1 ).
FIG. 1. Specificity of the ER␤ immunostaining and expression of ER␣ and ER␤ in endometrial structures during the menstrual cycle.
Consecutive endometrial sections were incubated with anti-ER␤ antibody alone (A) and preabsorbed with recombinant ER␤ peptide (B, 100 g/mL), as described in Materials and Methods. Note in B the disappearance of the immunostaining in glands and interstitium shown in A, when the anti-ER␤ antibody has been preincubated overnight with the specific peptide. C and D, proliferative phase (day 14). E and F, secretory phase (day 25). C, strong ER␣ immunolabeling in glandular and interstitial cells. D, weak ER␤ immunolabeling in the same structures. E, decreased glandular and interstitial expression of ER␣ in the secretory phase (compare with C). F, interstitial ER␤ labeling has increased with respect to the proliferative period (compare with D). Original magnification, ϫ200.
Vascular ER␤ immunolabeling is low throughout most of the menstrual cycle; however, it increases during the latesecretory phase both in intensity (Figs. 2D and 4 , B and D) and number of stained nuclei (Table 1 ) (ϫ3.3 and ϫ2.5; P Ͻ 0.05, as compared with the mid-and late-proliferative periods, respectively). Vascular ER␤ is predominantly expressed in parietal smooth muscle cells (CML) and occasionally in endothelial cells (Fig. 4, B and D) . Thus, while epithelial ER␤ immunolabeling is higher on days 14 and 15, interstitial and vascular ER␤ staining peaks in the late-secretory phase.
Simultaneous or differential expression of ER␣ and ER␤ during the cycle
It has been suggested that cell-specific effects of estrogenic action could vary according to the respective expression of ER␣ and ER␤ and to the potential for the formation of homodimers of each ER type, as well as of ER␣/ER␤ heterodimers (27) . To understand the cell-specific effects of estrogens in the human endometrium, we have analyzed the endometrial expression of ER␣ and ER␤ in serial sections throughout the menstrual cycle. Our main findings concern the stronger immunolabeling of ER␣ compared with that of ER␤ and the variations of expression of both receptors observed in the glandular, stromal, and vascular compartments according to the phase of the cycle (Table 1) .
Proliferative phase. Glandular epithelial, stromal, and vascular cells of the functional zone express both ER␣ and ER␤ (Table  1) . ER␤ immunolabeling is, however, less intense than that of ER␣, especially in the glands (Fig. 1, A, C, and D) . ER␤ labeling in epithelial cells peaks in the periovulatory period (days 14 and 15), and glandular ER␣ staining is stronger during the midproliferative and periovulatory period, leading to their significant coexpression in the periovulatory period (Fig. 1, C and D) .
Secretory phase. During the progression from early to latesecretory phase, glandular expression of ER␣ in the endometrial functional zone becomes markedly lower than in the proliferative phase, as described previously (1, 2) and confirmed in this study (Table 1) . A similar pattern of immunolabeling is observed for glandular ER␤, leading to a low coexpression of ER␣ and ER␤ in the mid-and late-secretory phase (Fig. 1, E and F) . In contrast, ER␤ immunolabeling in some stromal cells increases during the late-secretory period (days 25-27; Fig. 1F) .
ER␤ is present in stromal decidual cells of the functional zone
Stromal cells positive for ER␤ during the late-secretory period (days 25-27) have a particular morphology and are mostly situated around spiral arterioles (Fig. 2) ; they have a round shape and the general aspect of decidual stromal cells (Fig. 2, A and D) . To better characterize these cells, adjacent sections were incubated with a monoclonal antismooth ␣- actin antibody, as decidual stromal cells have been shown to express this microfilament (19) . As shown in Fig. 2 , B and D, ER␤-positive cells are also ␣-actin positive, but not ER␣ positive (Fig. 2C) .
RT-PCR analysis of human endometrial cells was used to confirm the expression of ER␤ in decidual stromal cells. As shown in Fig. 3 , it allows the detection of specific products having the expected size of 392 bp (ER␤). To compare ER␤ transcripts in different hormonal conditions, we developed a semiquantitative RT-PCR assay (see Materials and Methods; Refs. 25 and 26) . Stromal cells incubated with E 2 , progesterone, and EGF for 10 days produce more ER␤ mRNA in contrast with control cells or cells incubated for a shorter period (Fig. 3) ; these cells also express IGFBP, a marker of decidualization (data not shown).
Modulation of ER␣ and ER␤ in cells of the vascular wall from the functionalis
In addition to glandular and stromal cells labeling described previously (see Refs. 1 and 2 for ER␣) and reported in this study (for ER␤), nuclear ER␣ and ER␤ immunolabeling is also present in vascular smooth muscle cells and occasionally in endothelial cells of the vascular wall (Fig. 4) ; a semiquantitative analysis of the immunostaining demonstrates that the expression of receptors changes during the menstrual cycle (Table 1) . ER␣ staining of CML is restricted to the late-proliferative and early-secretory phases, when it is markedly high both in staining intensity and in number of labeled nuclei (Fig. 4A) . ER␤ is present in the wall of arterioles at a lower concentration than that of ER␣ during these periods, as deduced from the lower staining intensity (Fig.  4E) . In contrast, ER␤ markedly increases in vascular cells (mainly smooth muscle cells of spiral arteries) in the latesecretory period (day 25; Fig. 4 , B and D), both in terms of staining intensity and number of labeled cells, whereas ER␣ is absent during this period ( Fig. 4F and Table 1) .
Discussion
Our results demonstrate the presence of ER␤ in the epithelial, vascular, and stromal compartments of the human endometrial functional zone, sites known to express ER␣; ER␤ expression, however, is usually less prominent, and its cyclic changes are less evident than those of ER␣, especially in epithelial cells (1, 2) . Moreover, ER␤ is the predominant form of vascular ER in the late-secretory period (days 24 -26) , whereas vascular ER␣ is mainly observed during the late follicular phase, suggesting different regulations and functions of these two ER subtypes in the vessels.
Available data on the expression of ER␤ protein are restricted to animal species (8, 15, 16, 28, 29) , and studies in the human endometrium have only reported the expression of the corresponding mRNAs (13, 14) . Using previously characterized (15, 16) polyclonal antibodies that cross-react with human ER␤ antigen, we demonstrated the immunolocalization of ER␤ protein in the human endometrium; the specificity of the immunostaining was confirmed by its decrease after preincubation of the anti-ER␤ antibody with the recombinant immunogen peptide, but not with the recombinant ER␣ protein (30) ; the presence of ER␤ was also deduced from RT-PCR analysis in isolated endometrial and vascular cells (25) . The relative levels of ER␤ transcripts in uterine cells, as deduced from semiquantitative RT-PCR analysis, correlated with differences at the protein level. This simple method, which is based on the exponential nature of the PCR reaction and the use of a stable endogenous internal standard, has previously been validated using mathematical analysis and Northern blot experiments (26); however, it only permits an estimation of relative rather than absolute amounts of nucleic acids, and the results should be confirmed by quantitative methods. Compared with the presence of ER␤ in human and rat uteri (13, 15) , the reported absence of uterine ER␤ in the mouse (8) could be related to species differences, or to the phase of the cycle of the animals used in these experiments. The presence of ER␤ in glandular epithelial and stromal cells also agrees with a previous study of the human uterus using in situ hybridization (13) . Our results demonstrate that ER␤ mRNAs are, indeed, translated into proteins in these cell types. Comparison of both the staining intensity and the number of immunolabeled nuclei for each ER within each compartment using computerized image analysis allows the analysis of relative ER␣ and ER␤ expression in each cell type during the menstrual cycle; this methodology has been previously used for the analysis of expression of vascular endothelial growth factor and its receptors in the human endometrium (21) .
Our results indicate that glandular ER␤ expression predominantly occurs during the follicular phase and the early secretory period and is usually lower than that of ER␣, although potential differences in the affinity characteristics of the two antibodies cannot be excluded. These findings extend and complete previous data based on mRNAs studies (13) . The higher epithelial expression of ER␤ and ER␣ on days 14 -18 could modulate estrogen action in these cells at this period. The finding of the presence of ER␤ in the human endometrial glands is not unexpected, although the expression of this receptor in the uterus has been reported to be low or absent (8) . Disruption of the ER␣ gene results in some studies (11) in insensitivity to the effects of E 2 on oedema, hyperemia, RNA and DNA synthesis, mitosis, and cellular hyperplasia, whereas recent studies have shown the preservation of selective estrogen actions in the ␣ERKO uterus (12, 31) , including water retention and induction of secretory products (such as lactoferrin; Ref. 12) . The maintenance of these actions by the catecholestrogen 4-hydroxyestradiol, but not by E 2 , and the lack of inhibition of those effects by the pure estrogen antagonist ICI 182780 suggest the possibility of a non-ER␣-mediated signaling pathway (12) , possibly through activation of ER␤. Estrogenic effects, such as epithelial growth and stimulation of secretory products, have also been previously described in wild-type uterine epithelial cells lacking ER␣ (10, 32) . Thus, preservation of selective estrogenic effects in the ␣ERKO mouse uterus could also result from estrogenic action in ER␤-positive epithelial cells.
An important finding of our study is the presence of both ER␣ and ER␤ in human uterine vessels, mainly in smooth muscle cells of the vascular wall and occasionally in endothelial cells, and the fact that these receptors undergo different cyclic variations. The vascular ER␣ increase in the late-proliferative and early-secretory phases, which has not been described before, can be explained as an effect of the estrogen preovulatory surge, similarly to the E 2 -induced ER␣ increase observed in the rabbit uterine vessels (20) . Abundant evidence in the literature shows that steroid hormones play an active role in regulating cyclic endometrial vascular changes, vascular permeability, and blood flow (see Refs. 20, 24, and 33) that are essential for endometrial physiology and for successful nidation and reproduction. Endometrial vessels regenerate at the beginning of the ovarian cycle, proliferate and branch during the follicular phase, then coil into thick-walled spiral arteries in the luteal period to undergo collapse and sloughing at menses (24) . The observation of the presence of ERs at relatively high concentrations in smooth muscle cells of the vascular wall of uterine vessels (18, 20) has led to the conclusion of a direct action of this steroid on endometrial vasculature. Activation of vascular ER␣ receptors during the periovulatory period could be related to vasodilation, the production of paracrine factors in the vascular smooth muscle cells and their permeabilizing action on the vessels (20, 22, 34) . In the mid-late secretory phase (days 24 -26) , the finding that ER␤ is the predominant form of vascular ER, while vascular ER␣ levels are very low, suggests that ER␤ might play a role in the regulation of vascular function in this specific phase of the cycle. Vascular ER␤ is expressed both when the coiling of the spiral arterioles reaches its maximal level and when the decidual changes of the stromal cells surrounding those same arterioles occur (24) ; also ER␤ increases in late-proliferative decidual stromal cells and in decidual cells during pregnancy (unpublished data), suggesting some specific role of this receptor during the process of decidualization. Mice lacking ER␤ have been reported to be fertile, but have fewer and smaller litters than wild-type mice (35) ; this result was interpreted as the consequence of a direct loss of ER␤-mediated actions in the ovary. However, the ability of progesterone to in- 
The immunostaining was estimated semiquantitatively as: Ϫ, negative; Ϫ/ϩ, faint; ϩ, moderate; ϩϩ strong; and ϩϩϩ, very intense, as described previously (17, 19, 21 duce a decidual response in the absence of ER␣ in endometrial stromal cells of ␣ERKO mice with high E 2 levels (36) is a finding that could be explained through activation of the ER␤ in addition to activation of the progesterone receptor. The reasons for the appearance of substantial levels of ER␤ in human vascular and stromal cells during the mid-late luteal transition (days 24 -26) and the disappearance of the receptor during hormonal withdrawal (days 27-28) remain to be elucidated. Differences in tissue distribution of ER␤ and ER␣ during the menstrual cycle suggest the presence of analogous or distinct roles fulfilled by each receptor. ER␤ may, therefore, play a role in the modulation of estrogenic action, either in combination with ER␣ or by itself. It has been suggested that the potential for the formation of homodimers of each ER type, as well as heterodimers, can have differential effects on gene activation (27) . Moreover, ER␤ has been demonstrated to exert opposite transcriptional effects in comparison to ER␣, after binding to estrogens and antiestrogens in some promoter context (37) . The transcriptional activity in estrogen-responsive tissues may, therefore, be modulated by the ER-type and the relative content of each receptor. ER␤ may modulate the activity of ER␣ in glandular cells and possibly in cells of the vascular wall, especially during the lateproliferative and early-secretory phases when these cells coexpress the two receptors. Differences in the ER␣/ER␤ ratio among different hormonal conditions and in pathological disorders (38 -39) could have important functional implications, because these ERs have different binding characteristics (7) and different levels of expression are found in pathological conditions such as endometriosis (38, 39) . We also postulate that a decrease in the ER␣/ER␤ ratio in stromal and vascular cells at day 25 could influence endogenous gene expression during the decidualization process.
In summary, this study indicates the presence of ER␤ receptors in epithelial, stromal, and vascular cells of the human endometrium and describes their cyclic changes during the menstrual cycle. Our findings may explain the preservation of selective actions of estrogens in the ␣-ERKO mouse uterus, and provide a basis for the reinvestigation of specific actions of E 2 that are not mediated by ER␣ in the human endometrium. Further investigations into the ER␤-mediated signaling pathway, by which physiological estrogens or xeno-estrogens may activate nuclear processes, are needed to better elucidate the role of this receptor in endometrial cyclic functional changes.
